rss
J Neurol Neurosurg Psychiatry 75:1672-1677 doi:10.1136/jnnp.2003.028761
  • Paper

Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study

  1. R Katzenschlager1,2,
  2. A Evans1,
  3. A Manson3,
  4. P N Patsalos4,
  5. N Ratnaraj4,
  6. H Watt5,
  7. L Timmermann6,
  8. R Van der Giessen7,
  9. A J Lees1
  1. 1National Hospital for Neurology and Neurosurgery, London, UK
  2. 2Department of Neurology, Donauspital/SMZ-Ost, Vienna, Austria
  3. 3Wessex Neurological Centre, University of Southampton, Southampton, UK
  4. 4Department of Clinical and Experimental Epilepsy, Institute of Neurology, London, UK
  5. 5Medical Statistics Unit, London School of Hygiene and Tropical Medicine and Institute of Neurology, Queen Square, London, UK
  6. 6Department of Neurology, University of Düsseldorf, Düsseldorf, Germany
  7. 7Phytrix Ltd, Munich, Germany
  1. Correspondence to:
 Professor A J Lees
 Reta Lila Weston Institute of Neurological Studies, Windeyer Building, 46 Cleveland Street, London, W1T 4JF, UK; aleesion.ucl.ac.uk
  • Received 19 September 2003
  • Accepted 19 February 2004
  • Revised 23 January 2004

Abstract

Background: The seed powder of the leguminous plant, Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. We have assessed the clinical effects and levodopa (l-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard l-dopa/carbidopa (LD/CD).

Methods: Eight Parkinson’s disease patients with a short duration l-dopa response and on period dyskinesias completed a randomised, controlled, double blind crossover trial. Patients were challenged with single doses of 200/50 mg LD/CD, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. l-Dopa pharmacokinetics were determined, and Unified Parkinson’s Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 h following drug ingestion. Dyskinesias were assessed using modified AIMS and Goetz scales.

Results: Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak l-dopa plasma concentrations. Mean on time was 21.9% (37 min) longer with 30 g mucuna than with LD/CD (p = 0.021); peak l-dopa plasma concentrations were 110% higher and the area under the plasma concentration v time curve (area under curve) was 165.3% larger (p = 0.012). No significant differences in dyskinesias or tolerability occurred.

Conclusions: The rapid onset of action and longer on time without concomitant increase in dyskinesias on mucuna seed powder formulation suggest that this natural source of l-dopa might possess advantages over conventional l-dopa preparations in the long term management of PD. Assessment of long term efficacy and tolerability in a randomised, controlled study is warranted.

Footnotes

  • Mr Charles Burnett provided an unrestricted grant supporting all expenses for this study

  • Competing interests: R Van der Giessen is an employee of Phytrix Ltd, Munich

Podcasts
Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article